Offers Claimed: 113
Downloaded Today: 42
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers the following ways to purchase this medication. Choose the Best option for you!
Yes100% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$1 – $8
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your fluconazole prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
More frequently reported side effects include: vomiting. See below for a comprehensive list of adverse effects.For the Consumer
Applies to fluconazole: oral powder for suspension, oral tablet
Other dosage forms:
Along with its needed effects, fluconazole may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fluconazole:
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking fluconazole:
Symptoms of overdose
Some side effects of fluconazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
For Healthcare Professionals
Applies to fluconazole: intravenous solution, oral powder for reconstitution, oral tabletGeneral
This drug was generally well tolerated. Changes in renal and hematological function test results and hepatic abnormalities reported during therapy with this and comparative agents in some patients, primarily those with serious underlying diseases (e.g., AIDS, cancer); clinical significance and relationship to therapy unclear.
During clinical trials of single-dose therapy, side effects possibly related to therapy were reported in 26% of patients using this drug and 16% of patients using active comparative agents. The most common side effects reported in patients receiving a single 150 mg dose of this drug for vaginitis were headache, nausea, and abdominal pain. Most side effects were of mild to moderate severity.
During clinical trials of multiple-dose therapy, side effects were reported in 16% of patients. Therapy discontinuation occurred in 1.5% and 1.3% of patients due to adverse clinical events and laboratory test abnormalities, respectively. Clinical side effects were reported more often in HIV-infected patients than in non-HIV-infected patients (21% versus 13%), but the patterns in both groups were similar.Nervous system
Rare cases of seizures have been reported, but a causal relationship was difficult to establish, since some of these patients had cryptococcal meningitis or severe underlying disease. Nonetheless, at least 1 case of seizure following a 100 mg oral dose has been reported.
Seizures, dizziness, paresthesia, somnolence, tremor, and vertigo have also been reported during postmarketing experience.
Very common (10% or more): Headache (up to 13%)
Uncommon (0.1% to 1%): Seizures, dizziness, paresthesia, somnolence, vertigo, visual field defect, taste perversion, hyperkinesia, hypertonia
Rare (less than 0.1%): Tremor
Frequency not reported: DysesthesiasGastrointestinal
Very common (10% or more): Nausea, abdominal pain, diarrhea, vomiting
Common (1% to 10%): Dyspepsia
Uncommon (0.1% to 1%): Constipation, flatulence, loose stools, dry mouth
Frequency not reported: General abdominal discomfort
Dry mouth, dyspepsia, and vomiting have also been reported during postmarketing experience.Hepatic
Fatal hepatic reactions have occurred primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications. One reported patient with AIDS experienced acute hepatic necrosis and hepatic failure about 3 weeks after starting this drug.
Transient hepatic reactions have been reported in patients with no other identifiable risk factors. Liver function returned to baseline after stopping this drug.
Serum transaminase elevations (greater than 8 times the upper limit of normal [8 x ULN]; about 1%) and statistically significant increases in AST have been reported. Serum transaminase elevations have been reported primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications, including agents known to be hepatotoxic.
Transaminase elevations greater than 2 to 3 x ULN have also been reported.
Cholestasis, hepatocellular damage, and hepatocellular necrosis have also been reported during postmarketing experience.
Very common (10% or more): Increased ALT, increased AST
Uncommon (0.1% to 1%): Serum transaminase elevations, cholestasis, jaundice, increased bilirubin
Rare (less than 0.1%): Serious hepatic reactions, hepatic toxicity (including fatalities), hepatic failure, hepatocellular necrosis, hepatitis, hepatocellular damage
Frequency not reported: Hepatic reactions (ranging from mild transient transaminase elevations to clinical hepatitis, fulminant hepatic failure [including fatalities]), transient hepatic reactions (including hepatitis, jaundice), elevated liver function tests (transient and asymptomatic), cholestatic jaundice, fatal hepatic necrosis, increased plasma levels of hepatic enzymesDermatologic
Reversible alopecia has been associated with long-term (2 months or longer) therapy.
In patients with serious underlying diseases (primarily AIDS and malignancy), exfoliative skin disorders have resulted in a fatal outcome.
Acute generalized exanthematous pustulosis, drug eruption, increased sweating, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), and alopecia have also been reported during postmarketing experience.
Very common (10% or more): Rash
Common (1% to 10%): Maculopapular erythema
Uncommon (0.1% to 1%): Pruritus, genital pruritus, erythematous rash, dry skin, abnormal skin odor, urticaria, herpes simplex, drug eruption, increased sweating
Rare (less than 0.1%): Angioedema, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), alopecia, acute generalized exanthematous pustulosis, exfoliative dermatitis
Frequency not reported: Reversible alopecia, exfoliative skin disorders (including fatalities)Metabolic
Very common (10% or more): Increased blood alkaline phosphatase
Uncommon (0.1% to 1%): Hypokalemia, anorexia, decreased appetite
Rare (less than 0.1%): Hypercholesterolemia, hypertriglyceridemia
Hypercholesterolemia, hypertriglyceridemia, and hypokalemia have also been reported during postmarketing experience.Hypersensitivity
Rare cases of exfoliative dermatitis and ulcerative eruptions consistent with Stevens-Johnson syndrome have been reported in association with hypersensitivity reactions.
A 52-year-old female experienced a fixed drug eruption (FDE) when administered a single 400 mg oral dose for extensive pityriasis versicolor. Within 12 hours, she noticed 3 oval, painful, eroded, pigmented patches over her trunk with diameters of 3 to 4 cm and erythematous halos. A clinical diagnosis of FDE due to drug therapy was made. The FDE was confirmed when the patient was rechallenged with a 25 mg oral dose.
Rare (less than 0.1%): Anaphylactic reaction, anaphylaxis
Frequency not reported: Hypersensitivity reactions (including generalized edema, stridor, hypotension, exfoliative dermatitis, ulcerative eruptions), fixed drug eruption
Postmarketing reports: Anaphylaxis (including angioedema, face edema, pruritus)Cardiovascular
Most reports of QT interval prolongation and torsades de pointes involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications that may have been contributory.
An 11-year-old male with neurofibromatosis-1 presented to the hospital in septic shock secondary to a perforated gastric volvulus. After initial stabilization, the patient underwent total gastrectomy and multiple peritoneal lavages. Culture of peritoneal fluid showed infection with Candida albicans. Therapy was started with fluconazole 150 mg IV every 12 hours. After starting this drug, the patient developed QT prolongation and complex ventricular arrhythmia. The drug was discontinued. Over the subsequent 36-hours, the patient remained in sinus rhythm except for one brief run of ventricular bigeminy. An ECG recorded 5 months after admission (and about 4 months after cessation of all QT-prolonging medications) showed sinus rhythm with normal heart rate and corrected QT interval.
QT prolongation and torsade de pointes have also been reported during postmarketing experience.
Rare (less than 0.1%): QT prolongation, torsade de pointes
Frequency not reported: Prolongation of the QT interval on the ECG, palpitations, complex ventricular arrhythmiaHematologic
Anemia, eosinophilia, leukopenia, neutropenia, and thrombocytopenia have been reported, often in patients with severe deep fungal infections or underlying disease.
Spontaneous reports of anemia were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of anemia in the elderly. A causal relationship to drug exposure could not be determined.
Anemia, leukopenia, neutropenia, agranulocytosis, and thrombocytopenia have also been reported during postmarketing experience.
Uncommon (0.1% to 1%): Anemia
Rare (less than 0.1%): Leukopenia, neutropenia, agranulocytosis, thrombocytopenia
Frequency not reported: EosinophiliaOther
Uncommon (0.1% to 1%): Thirst, fatigue, malaise, pain, rigors, asthenia, fever, flushing, hot flushes
Rare (less than 0.1%): Face edema
Frequency not reported: Infection due to resistant microorganisms
Fever, asthenia, fatigue, and malaise have also been reported during postmarketing experience.Musculoskeletal
Uncommon (0.1% to 1%): Back pain, myalgia
Frequency not reported: Joint pain, finger stiffness
Myalgia has also been reported during postmarketing experience.Psychiatric
Uncommon (0.1% to 1%): Insomnia, nervousness
Insomnia has also been reported during postmarketing experience.Renal
Uncommon (0.1% to 1%): Polyuria, renal pain, changes in renal function tests
Frequency not reported: Membranous nephropathy
Postmarketing reports: Acute renal failure
A 58-year-old female with a history of hypertension and cervical cancer experienced membranous nephropathy coincident with this drug. The patient presented with increasing generalized edema accompanied by nausea and indigestion for 3 weeks. Clinical findings showed the patient had stage I membranous nephropathy. At initial presentation, the patient's medication history included amlodipine, hydrochlorothiazide, metoclopramide, and levosulpiride. She did not admit to taking fluconazole. Five months after the initial presentation, the patient returned with reports of increasing pedal edema. At that point, the patient admitted to taking this drug once a week for tinea pedis. The patient went into complete remission when the drug was stopped.
Spontaneous reports of acute renal failure were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of renal failure in the elderly. A causal relationship to drug exposure could not be determined.Genitourinary
Uncommon (0.1% to 1%): Intermenstrual bleeding, dysmenorrhea, leukorrhea, menorrhagia, uterine spasm, vaginal disorders, female sexual dysfunctionRespiratory
Uncommon (0.1% to 1%): Pharyngitis
Frequency not reported: Respiratory disordersOcular
Uncommon (0.1% to 1%): Abnormal vision